Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial
Imperial College London · Eli Lilly (United States) · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
58
total citations
- FWCI
- 64.53
- Percentile
- 100%
- References
- 31
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Double blind
- Medicine
- Placebo
- Internal medicine
- Pharmacology
- Pathology
- Alternative medicine
No related works found for this paper.